IPCA Laboratories is currently trading at Rs. 680.20, up by 15.90 points or 2.39% from its previous closing of Rs. 664.30 on the BSE.
The scrip opened at Rs. 670.00 and has touched a high and low of Rs. 687.40 and Rs. 662.00 respectively. So far 67,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 744.05 on 11-Oct-2013 and a 52 week low of Rs. 401.10 on 08-Nov-2012.
Last one week high and low of the scrip stood at Rs. 703.70 and Rs. 661.10 respectively. The current market cap of the company is Rs. 8,537 crore.
The promoters holding in the company stood at 45.89% while Institutions and Non-Institutions held 37.53% and 16.58% respectively.
The company has reported 3.49% rise in its net profit at Rs 129.45 crore for the quarter as compared to Rs 125.09 crore for the same quarter in the previous year. Total income of the company has increased by 10.24% at Rs 846.70 crore for quarter under review as compared to Rs 768.08 crore for the quarter ended September 30, 2012.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
Source:- berkeleygains
The scrip opened at Rs. 670.00 and has touched a high and low of Rs. 687.40 and Rs. 662.00 respectively. So far 67,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 744.05 on 11-Oct-2013 and a 52 week low of Rs. 401.10 on 08-Nov-2012.
Last one week high and low of the scrip stood at Rs. 703.70 and Rs. 661.10 respectively. The current market cap of the company is Rs. 8,537 crore.
The promoters holding in the company stood at 45.89% while Institutions and Non-Institutions held 37.53% and 16.58% respectively.
The company has reported 3.49% rise in its net profit at Rs 129.45 crore for the quarter as compared to Rs 125.09 crore for the same quarter in the previous year. Total income of the company has increased by 10.24% at Rs 846.70 crore for quarter under review as compared to Rs 768.08 crore for the quarter ended September 30, 2012.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
Source:- berkeleygains